Abstract Background Ipilimumab (Ipi) improves the survival of advanced melanoma patients
with an incremental long-term benefit in 10–15% of patients. A tumor signature that …

Background Immune checkpoint inhibitors (ICI) can lead to long-term responses in patients
with metastatic melanoma. Still many patients with melanoma are intrinsically resistant or …

Background Ipilimumab induces long-lasting clinical responses in a minority of patients with
metastatic melanoma. To better understand the mechanism (s) of action and to identify novel …

Background Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-
lymphocyte antigen-4, has demonstrated an improvement in overall survival in two phase III …

Background Ipilimumab can induce durable disease control and long-term survival in
patients with metastatic melanoma. Identification of a biomarker that correlates with clinical …

Ipilimumab has revolutionized malignant melanoma therapy, but a better understanding of
the mechanisms behind treatment response and adverse effects is needed. In this work, the …

9008 Background: Ipilimumab is a fully human monoclonal antibody to cytotoxic T-
lymphocyte antigen-4. Identifying predictive markers may help select advanced melanoma …

Purpose Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) for metastatic
melanoma can be highly effective, but attrition due to progression before TIL administration …

Background Ipilimumab is an approved immunotherapy that has shown an overall survival
benefit in patients with cutaneous metastatic melanoma in two phase III trials. As results of …

Despite the recent successes and durable responses with immune checkpoint inhibitors
(ICI), many cancer patients, including those with melanoma, do not derive long-term benefits …